A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell engager." This type of immunotherapy ignites our own ...
Pfizer Inc. PFE shares are up during Thursday’s trading session after the company shared data from Talzenna plus Xtandi’s investigational treatment regimen for HRR gene-mutated metastatic ...
InvestorsHub on MSN
Pfizer’s TALZENNA combination shows progress against prostate cancer
Pfizer Inc. (NYSE:PFE) announced that its Phase 3 TALAPRO-3 clinical trial met its primary endpoint, demonstrating that the combination of TALZENNA (talazoparib) and XTANDI (enzalutamide) ...
This may not apply in your husband’s case, but it’s worth having the conversation. The two meds Goldstein prescribes for men are flibanserin (Addyi), an oral tablet taken d ...
Earlier deployment of ARPIs, PARP inhibitors, and PSMA radioligand therapy yields deeper initial control but creates heavily pretreated mCRPC with complex resistance and cumulative toxicity ...
Pfizer (PFE) stock is in focus as Xtandi, marketed with Astellas (ALPMF), and cancer drug Talzenna succeed in a Phase 3 trial for prostate cancer. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results